The outlook of companies tied to Viagra's past presents a challenging investment scenario . While the initial surge generated substantial profits , generic competition have significantly eroded revenue. Investing in related pharmaceutical companies now requires a discerning assessment of patent safeguards, evolving patient shifts , and the prospect